Nuvonis_Tech's profile picture. Providing the gene therapy & vaccine sector with excellent serum free Vero cell banks and one / two step purification technology.

Nuvonis Technologies

@Nuvonis_Tech

Providing the gene therapy & vaccine sector with excellent serum free Vero cell banks and one / two step purification technology.

Nuvonis Technologies reposted

Scientists have used CRISPR to alter the color, shape, and rigidity of butterfly wings. cell.com/cell-reports/f…

ajitjohnson_n's tweet image. Scientists have used CRISPR to alter the color, shape, and rigidity of butterfly wings. cell.com/cell-reports/f…

Nuvonis Technologies reposted

Thank you for visiting us at ESHRE! We have received overwhelming positive response especially on our AuVis Vitrification System prototype. We hope that you enjoyed the conference as much as we did. We are looking forward to seeing you all again soon. #ESHRE

EscoLifesci's tweet image. Thank you for visiting us at ESHRE! We have received overwhelming positive response especially on our AuVis Vitrification System prototype. 

We hope that you enjoyed the conference as much as we did. We are looking forward to seeing you all again soon. #ESHRE

Nuvonis Technologies reposted

More people in U.S. have Tattoos than iPhones. Removal has several current issues: 1) many treatments required 2) doesn’t work on all ink colors 3) on darker skin it destroys pigment 4)painful. Have investigated (and invested) @Lux_Capital


Nuvonis Technologies reposted

New VC firm out of stealth today. Angular Ventures. Early stage. Enterprise. Deep Tech. European + Israeli companies with global (US) ambition. angularventures.com


Nuvonis Technologies reposted

What is CAR T-cell therapy? It involves changing a patient’s immune cells in the lab so they'll attack cancer cells. cancer.gov/publications/d… #AACR18

theNCI's tweet image. What is CAR T-cell therapy? It involves changing a patient’s immune cells in the lab so they'll attack cancer cells. cancer.gov/publications/d… #AACR18

Nuvonis Technologies reposted

Dr. Lei Wang from Syndax Pharmaceuticals presents preclinical data on NKTR-214 + entinostat at #AACR18. Access the poster here: bit.ly/2HomkkO

NektarNews's tweet image. Dr. Lei Wang from Syndax Pharmaceuticals presents preclinical data on NKTR-214 + entinostat at #AACR18. Access the poster here: bit.ly/2HomkkO

Nuvonis Technologies reposted

A major theme for the future research in #Immunotherapy is Tissue-Specific Immunoregulation. Surprisingly we have very little data on organ-specific regulation of immunity. Very little such data at #AACR18 Check out this superb review by William Pao cancerdiscovery.aacrjournals.org/content/8/4/39…

jsoriamd's tweet image. A major theme for the future research in #Immunotherapy is Tissue-Specific Immunoregulation. Surprisingly we have very little data on organ-specific regulation of immunity. Very little such data at #AACR18
Check out this superb review by William Pao
cancerdiscovery.aacrjournals.org/content/8/4/39…

Nuvonis Technologies reposted

analyses of more than 10,000 tumors identified six immune subtypes that encompass multiple cancer types and are hypothesized to define immune response patterns impacting prognosis cell.com/immunity/fullt…

jsoriamd's tweet image. analyses of more than 10,000 tumors identified six immune subtypes that
encompass multiple cancer types and are hypothesized to define immune response patterns impacting prognosis
cell.com/immunity/fullt…

Nuvonis Technologies reposted

China biotechs must globalize product development to ensure ROI (given lower reimbursement in home market) - Fountain Medical Chairman Dan Zhang, Suzhou Founder's Club spring meeting


Nuvonis Technologies reposted

To all apologies for the link provided, this is the direct one cell.com/immunity/fullt… That being said this is truly a must read

Genetic aberrations in cancer cells dictate the immune contexture of tumors A must read …-ncbi-nlm-nih-gov.iscape.idm.oclc.org/pubmed/29562192

jsoriamd's tweet image. Genetic aberrations in cancer cells dictate the immune contexture of tumors
A must read
…-ncbi-nlm-nih-gov.iscape.idm.oclc.org/pubmed/29562192


Nuvonis Technologies reposted

It's raining money! Martin Münchbach shares his best #strategies for #fundraising 🤑 #bbbiotech #VentureCapital #startup goo.gl/JHsbnV


Nuvonis Technologies reposted

Genetic aberrations in cancer cells dictate the immune contexture of tumors A must read …-ncbi-nlm-nih-gov.iscape.idm.oclc.org/pubmed/29562192

jsoriamd's tweet image. Genetic aberrations in cancer cells dictate the immune contexture of tumors
A must read
…-ncbi-nlm-nih-gov.iscape.idm.oclc.org/pubmed/29562192

Nuvonis Technologies reposted

Harald Isemann chairman of @viennabiocenter is presenting their amazing campus to our @GotoGrow_London Life Science delegation @L_Pbusiness

Alban_remy's tweet image. Harald Isemann chairman of @viennabiocenter is presenting their amazing campus to our @GotoGrow_London Life Science delegation @L_Pbusiness

Nuvonis Technologies reposted

Hong Kong is accelerating its plans, biotech listing rules will be finalized in April, 1st IPO applications in May - Michael Chan, HKEX #BIOASIA18


Nuvonis Technologies reposted

Remember that $133M deal Mirati Therapeutics signed with Beigene in January? At #BIOASIA18, Mirati's Christopher LeMasters says that, in light of the many many combo I-O trials underway, a key win was unlocking access to new trial populations in China.


Nuvonis Technologies reposted

The stars have aligned in the Hong Kong market, says Michael Chan, SVP of HKEX, with 3 pools of investors fueling liquidity: Western institutional investors, Asian investors inc. sovereign wealth, and mainland Chinese investors, unable to invest abroad, coming to HK #BIOASIA18


Nuvonis Technologies reposted

Zai Lab BD director Jonathan Wang said China's govt. is always trying new things with companies, wanting to see what works. Partnering with regulators, as Zai has done, is an important exercise in building trust, avoiding risk, he added. #BIOASIA18


Nuvonis Technologies reposted

#BreakingNews: Novartis licenses biomaterial systems from @Harvard for delivering cancer immunotherapy #NovartisNews


Nuvonis Technologies reposted

C-Bridge Capital managing director Tong Zhang, speaking at #BIOASIA18, says the firm has invested the majority of its current $400 million fund (almost x 2 with LP contributions) and is now raising a new fund.


United States Trends

Loading...

Something went wrong.


Something went wrong.